Related Experiment Video
Updated: Jun 13, 2026
09:56
Implantation of Combined Telemetric ECG and Blood Pressure Transmitters to Determine Spontaneous Baroreflex Sensitivity in Conscious Mice
Published on: February 14, 2021
Baroreflex stimulation in antihypertensive treatment.
Jeremy G Taylor1, John D Bisognano
1Department of Internal Medicine, Nephrology Division, University of Rochester, 601 Elmwood Avenue, Box 679-7, Rochester, NY 14642-8679, USA.
Current Hypertension Reports
|April 29, 2010
Summary
Baroreflex stimulation therapy, using carotid sinus stimulators, shows promise for treating hypertension. This non-pharmacologic approach may help patients reach blood pressure goals by inhibiting the sympathetic nervous system.
Area of Science:
- Cardiovascular medicine
- Nephrology
- Biomedical engineering
Background:
- Hypertension is a major global health issue, with many patients not achieving target blood pressure goals despite medication.
- Non-pharmacologic therapies are gaining interest due to the limitations of current treatments.
- Carotid sinus baroreceptor stimulation can lower blood pressure by reducing sympathetic nervous system activity.
Purpose of the Study:
- To evaluate the safety and efficacy of implantable carotid sinus stimulators for treating chronic hypertension.
- To explore the potential of baroreflex stimulation therapy as a novel approach to blood pressure management.
Main Methods:
- Development and study of implantable carotid sinus stimulators in animal and human models.
- Investigating the mechanism of blood pressure reduction via inhibition of renal sympathetic tone.
Main Results:
- Early studies indicate that baroreflex stimulation therapy is a promising modality for blood pressure control.
- The therapy has demonstrated the potential to reduce blood pressure by modulating sympathetic nervous system activity.
Conclusions:
- Implantable carotid sinus stimulators represent a potential future therapy for managing hypertension, especially resistant cases.
- Ongoing research will further elucidate the long-term safety and effectiveness of baroreflex stimulation therapy.
More Related Videos
Related Concept Videos
01:18Neural Regulation of Blood Pressure
The neural regulation of blood pressure involves intricate interactions between the autonomic nervous system (ANS) and cardiovascular system, ensuring adequate perfusion of tissues. This regulation primarily occurs through baroreceptor and chemoreceptor reflexes, involving both short-term and long-term mechanisms.
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:18Hypertension and Regulation of Blood Pressure
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...